Sandoz Can't Get New Trial After $39M Eyelash Serum IP Loss
A Colorado federal judge denied a new trial bid by Novartis' generic-drug making arm Sandoz over a patent covering a drug to grow eyelashes after a jury awarded $39 million to...To view the full article, register now.
Already a subscriber? Click here to view full article